Objective To explore the treatment effect of Victoza (Liraglutide Injection) and Rosuvastatin in type 2 diabetes with hyperlipemia.Methods 60 cases of type 2 diabetes combined with hyperlipemia from October 2011 to April 2012 in the people's hospital of Handan City were selected and randomly divided into the study group and the control group with 30 cases in each group, patients of the study group were treated with Victoza and Rosuvastatin, patients of the control group were given Novolin combined with Simvastatin, treatment effects of two groups were compared.Before treatment, 3 and 6 months after treatment, blood glucose, lipid parameters of patients in two groups were detected and compared.Results After 3 and 6 months treatment, the FPG 2 h PG, HbA1.all decreased significantly, the differences were statistically significant (P < 0.05), but the FPG, 2 h PG, HbA1c of study group were lower than control group, the differences were statistically significant (P < 0.05).After 3 months of treatment, TC, TG, LDL-C of study group were lower than before treatment (P < 0.05), HDL-C increased (P < 0.05); after 6 months of treatment, TC, TG, LDL-C of the study group continued to reduce (P < 0.05), HDL-C increased too (P < 0.05).After 3 months of treatment,TC, TG of control group decreased significantly (P < 0.05 ), HDL-C increased (P < 0.05), LDL-C had no significant differences (P > 0.05); after 6 months of treatment, TC, TG, LDL-C of the control group were lower than before treatment (P < 0.05), HDL-C increased (P < 0.05); after 3, 6 months of treatment, TC, TG, LDL-C of the study group were significantly lower than the control group.HDL-C was significantly higher than that in the control group, difference between the two groups was significant (P < 0.05).Conclusion Hypoglycemic and hypolipidemic effect of Victoza combined Rosuvastatin in the treatment of type 2 diabetes with hyperlipidemia is significantly superior to the traditional treatment, with high effectiveness and strong hypolipidemic effect, it is worthy of clinical application.%目的 探讨诺和力(利拉鲁肽注射液)和瑞舒伐他汀对2型糖尿病合并高脂血症患者的治疗效果.方法 选择河北省邯郸市人民医院2011年10月～2012年4月收治的2型糖尿病合并高脂血症患者60例,随机分为研究组和对照组,每组各30例.研究组患者给予诺和力联合瑞舒伐他汀治疗,对照组给予诺和灵联合辛伐他汀治疗,比较两组治疗效果,治疗前、治疗3、6个月检测两组患者血糖、血脂指标,并进行组间比较.结果 两组治疗3、6个月后空腹血糖(FPG)、餐后2h血糖(2 h PG)、糖化血红蛋白(HbA1c)均明显下降,差异有统计学意义(P＜0.05),研究组治疗3、6个月时患者FPG、2 hPG、HbA1c低于对照组,差异有统计学意义(P＜0.05).研究组治疗3个月时总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)均较治疗前降低(P＜0.05),高密度脂蛋白胆固醇(HDL-C)升高(P＜0.05)；治疗6个月时研究组TC、TG、LDL-C继续降低(P＜0.05),HDL-C升高(P＜0.05)；对照组治疗3个月时TC、TG明显降低(P＜0.05),HDL-C升高(P＜0.05),LDL-C无明显改变(P＞0.05),治疗6个月时对照组TC、TG、LDL-C均降低(P＜0.05),HDL-C升高(P＜0.05)；治疗3、6个月时研究组TC、TG、LDL-C均明显低于对照组,HDL-C明显高于对照组,组间比较差异有统计学意义(P＜0.05).结论 诺和力联合瑞舒伐他汀治疗2型糖尿病合并高脂血症,降糖及降血脂效果均明显优于传统治疗,有效性高,调脂力强,值得临床推广应用.
展开▼
